Stocks
Annovis Bio, Inc.ANVS
NYSEHealthcareBiotechnology$1.00
Price as of · delayed, not real-time
Annovis Bio is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's. Its lead candidate, buntanetap, targets multiple pathways implicated in neurodegeneration. Investors track the company for its potential to address high unmet medical needs in these large patient populations.
52W Range: $0.95-$5.50
Congressional Interest in Annovis Bio, Inc. (ANVS)
No congressional trades have been disclosed for Annovis Bio, Inc. (ANVS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ANVS?
No congressional trades found for this stock.